Growth Hormone

IGF-1 DES

Des(1-3) IGF-1 (Truncated Insulin-like Growth Factor 1)

10x more potent than IGF-1 with no binding protein interference

IGF-1 DES is a truncated version of IGF-1 missing the first three amino acids. This modification makes it approximately 10 times more potent because it cannot be sequestered by IGF binding proteins.

IGF
💉

Admin routes

Subcutaneous, Intramuscular

🔬

Popularity

Niche

⚠️

Side effects

Monitor closely

🏪

AU vendors

0 rated

Key benefits

1Approximately 10x more potent than standard IGF-1
2Not sequestered by IGF binding proteins
3Short half-life allows targeted, localised application
4Promotes muscle cell hyperplasia (new cell creation) in vitro

📈What to expect

1
Immediate

Blood sugar drop possible within 30 minutes, have carbs available

2
Week 2-4

Localised muscle fullness and pump in injected areas

3
Week 4-6

Measurable size increases in targeted muscles reported by users

Based on community reports and published research. Individual results vary significantly.

💊Dosing protocols

Localised muscle growth (community protocol)

Dose

20-50 mcg

Frequency

Injected bilaterally into target muscle, pre or post workout

Duration

4-6 week cycles

Dosing information is sourced from published research and community protocols. This is not a recommendation. Consult a healthcare professional.

Research status|Research compound - used in in vitro and animal studies

Overview

IGF-1 DES (des(1-3) IGF-1) is a naturally occurring variant of IGF-1 found in the human brain during fetal development. The removal of the N-terminal tripeptide (Gly-Pro-Glu) eliminates its ability to bind to IGF binding proteins (IGFBPs), which normally sequester and inactivate circulating IGF-1. Because IGFBPs cannot neutralise it, IGF-1 DES has roughly 10-fold greater biological potency than full-length IGF-1 LR3. It has a very short half-life (20-30 minutes) compared to IGF-1 LR3 (20-30 hours), making it suitable for localised, site-specific use.

⚙️How it works

IGF-1 DES binds to and activates the IGF-1 receptor (IGF-1R) with similar affinity to full-length IGF-1. Once IGF-1R is activated, it triggers the PI3K/AKT pathway (promoting cell survival and protein synthesis) and the RAS/MAPK pathway (promoting cell proliferation and differentiation). Because it is not bound by IGFBPs, all administered IGF-1 DES is bioavailable and active, resulting in much higher effective potency per microgram.

Side effects

Hypoglycaemia (potent insulin-like activity)
seriousCommon
Localised pain and swelling at injection site
mildCommon
Potential for accelerated growth of existing tumours (IGF pathway)
seriousRare

📅Research history

1988

Francis et al. characterise des(1-3) IGF-1 from bovine colostrum

References

  1. [1]Francis GL, et al. 'Insulin-like growth factors 1 and 2 in bovine colostrum. Sequences and biological activities compared with those of a potent truncated form.' Biochemical Journal, 1988.

Frequently asked questions

Related peptides

Community experiences

Share your experience with IGF-1 DES. Effects, side effects, protocol details - help others make informed decisions.

Write a review

Rating:

No community reviews yet. Be the first to share your experience with IGF-1 DES.

Need to calculate your dose?

Use our free reconstitution calculator to work out syringe units for IGF-1 DES.

Open Calculator

Found this useful?

Share this guide

Disclaimer: This guide is for educational and informational purposes only. It is not medical advice. The dosing protocols listed are sourced from published research and community reports and do not constitute a recommendation. Always consult a qualified healthcare professional before using any peptide. Australian regulations classify many peptides as Schedule 4 (prescription-only) substances. Check current TGA guidelines before purchasing.